Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Dicerna Pharmaceuticals Inc.
DescriptionKRAS dicer substrate short interfering RNA targeting multiple cancers
Molecular Target K-Ras (KRAS)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerKyowa Hakko Kirin Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today